The primary goal is to evaluate nirogacestat in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). Half of the participants will receive nirogacestat while the other half will receive placebo. NIR-DT-301: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Vers ...More
To learn more about available clinical trials related to brain and spinal tumors, contact us at cancer@cchmc.org or 513-636-2799.